{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:33:13Z","timestamp":1791232393747,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.clinthera.2012.01.014","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T12:34:43Z","timestamp":1329395683000},"page":"511-520","source":"Crossref","is-referenced-by-count":70,"title":["Pazopanib for the Treatment of Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Amy M.","family":"Pick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Nystrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.01.014_bib1","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1056\/NEJMra043172","article-title":"Renal cell carcinoma","volume":"353","author":"Cohen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.01.014_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"61","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2012.01.014_bib4","series-title":"Cancer: Principles and Practice of Oncology","first-page":"1139","article-title":"Cancers of the genitorurinary system: cancer of the kidney","author":"Linehan","year":"2006"},{"key":"10.1016\/j.clinthera.2012.01.014_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00280-009-0983-z","article-title":"Treatment of metastatic renal cell carcinoma","volume":"64","author":"Reeves","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clinthera.2012.01.014_bib6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/156800908785133132","article-title":"Targeting angiogenesis in renal cell carcinoma","volume":"8","author":"Lainakis","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.clinthera.2012.01.014_bib7","series-title":"American Joint Committee on Cancer: AJCC Cancer Staging Manual","first-page":"323","article-title":"Kidney","year":"2002"},{"key":"10.1016\/j.clinthera.2012.01.014_bib8","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2003.02.014","article-title":"Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial","volume":"21","author":"Clark","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.01.014_bib9","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.2003.02.005","article-title":"Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group\/Intergroup trial","volume":"21","author":"Messing","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.01.014_bib10","first-page":"187","article-title":"Interferon in metastatic renal cell carcinoma","volume":"27","author":"Fossa","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clinthera.2012.01.014_bib11","article-title":"Immunotherapy for advanced renal cell cancer","volume":"1","author":"Coppin","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2012.01.014_bib12","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 225 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.01.014_bib13","series-title":"Votrient (pazopanib)","year":"2011"},{"key":"10.1016\/j.clinthera.2012.01.014_bib14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11912-007-0007-2","article-title":"Pazopanib: a novel multitargeted tyrosine kinase inhibitor","volume":"9","author":"Sonpavde","year":"2007","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clinthera.2012.01.014_bib15","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2012.01.014_bib18","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1517\/14656560903436493","article-title":"Pazopanib: therapeutics developments","volume":"10","author":"Limvorasak","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2012.01.014_bib19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","article-title":"Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma","volume":"28","author":"Hutson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.01.014_bib20","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2012.01.014_bib21","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2012.01.014_bib22","series-title":"Sutent (sunitinib)","year":"2008"},{"key":"10.1016\/j.clinthera.2012.01.014_bib23","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S1359-6349(09)71452-1","article-title":"Renal cancer quality of life (QOL) in treatment-na\u00efve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) treated with pazopanib: results from a phase III double-blind, placebo-controlled trial","volume":"7","author":"Hawkins","year":"2009","journal-title":"EJC Supplements"},{"key":"10.1016\/j.clinthera.2012.01.014_bib24","series-title":"Nexavar (sorafenib)","year":"2008"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812000197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812000197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T04:23:13Z","timestamp":1543206193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812000197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0149291812000197"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.01.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}